Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

Cardiovascular Drug Reviews

Volumn 21, Issue 3, 2003, Pages 199-215

  Kajinami, Kouji ^a   Takekoshi, Noboru ^b   Saito, Yasushi ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Atherosclerosis; Drug interactions; HMG CoA reductase inhibitors; LDL cholesterol; Lipid lowering drugs; NK 104; Pitavastatin

Indexed keywords

ATORVASTATIN; ATORVASTATIN LACTONE; CERIVASTATIN; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DICLOFENAC; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LACTONE; MEVINOLIN; NICARDIPINE; PITAVASTATIN; PITAVASTATIN LACTONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IC 50; LIPOPROTEIN METABOLISM; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

EID: 0141988934     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00116.x     Document Type: Review

References (80)

1. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel syntheic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittellforschung 1997;47:904-909.
2. Aoki T, Yamazaki H, Suzuki H, et al. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung 2001;51: 197-203.
3. Aoki T, Yoshinaka Y, Yamazaki H, et al. Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia. Eur J Pharmacol 2002;444:107-113.
4. Aoki T, Yamazaki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia. Arzneimittelforschung 2003;53:154-158.
5. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-129.
6. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685491.
7. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-1192.
8. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti. Safety considerations for statins. Curr Opin Lipidol 2002;13:637-644.
9. Boyed RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein mediated secretion. J Clin Pharmacol 2000;40:91-98.
10. Christians U, Jacobsen W, Floren L. Metabolism and drug interactions with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: Are the statins mechanistcally similar? Pharmacol Ther 1998;80:1-34.
11. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bemini F. New insights into the pharmacodynamic and phannacokinetic properties of statins. Pharmacol Ther 1999;84: 413-428.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
13. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19:740-748.
14. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999;27:410-416.
15. Fujino H, Kojima J, Yamada Y, Kanda H, Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xeno Metab Disp 1999;14:79-91.
16. Fujino H, Yamada I, Kojima J, Hirano M, Matsumoto H, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xeno Metab Disp 1999;14:415-424.
17. Fujino H, Yamada I, Shimada S, Yoneda M. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay - inhibitory effect of NK-104, a new inhbitior of HMG-CoA reductase. J Chromatogr B 2001;757:143-150.
18. Fujino H, Yamada I, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase - Effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdrla/b gene disruption on tissue distribution in mice. Drug Metabol Pharmacokin 2002;17:449-456.
19. Fujino H, Saito T, Tsunenari Y, Kojima J. Interaction between several medicines and statins. Arzneimittelforschung 2003;53:145-153.
20. Fujino H, Shimada S, Yamada I, Tsunenari Y, Hirano M, Kojima J. Interaction between fibrates and statins. In: Abstract of 13th International conference on cytochromes P450, 2003 (in Czech).
21. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003;33:27-41.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360: 7-22.
23. Hohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 2002;25:279-285.
24. http://www.crestor.com (online).
25. Igel M, Sudhop T, Bergmann. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatain and pitavastatin. J Clin Pharmacol 2002;42:835-845.
26. Ishikawa T, Allikimets R, Dean M, Higgins C, Ling V, Wain HM. New nomenclature of human ABC transporter genes. Xenobio Metabol Dispos 2000;15:8-19.
27. Jacobsen W, Kuhn B, Soldner A. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atrovastatin. Drug Metab Dispos 2000;28:1369-1378.
28. Kajinami K, Koizumi J, Ueda K, et al. NK-104 Study Group. Effects of NK-104, a new hydroxy-methylglutaryl coenzyme A reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 2000;85:178-183.
29. Kajinami K, Mabuchi H, Saito Y. NK-104: A novel synthetic HMG-CoA reductase inhibitor. Exp Opin Invest Drugs 2000;9:2653-2661.
30. Kantola T, Krivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharamacol Ther 1998;63:397-402.
31. Kantola T, Krivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
32. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (I): Absorption, distribution, metabolism and excretion in rats. Xeno Metab Disp 1998;13:484-498.
33. Kitahara M, Kanaki T, Toyoda K, et al. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Jpn J Pharmacol 1998;77:117-128.
34. Kojima J, Ohshima T, Yoneda M, Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Xeno Metab Disp 2001;16:497-502.
35. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69:340-345.
36. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-425.
37. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-130.
38. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000;7:138-144.
39. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb 2002;9:178-183.
40. Mück W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39:99-116.
41. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
42. Nakaya N, Uebaba K, Takebe M, Kojima J. A Phase 1 clinical study of a novel HMG-CoA reductase inhibitor, NK-104 (pitavastatin). Results of single and 7-day repeated oral administration studies in healthy adult male volunteers. J Clin Ther Med 2001;17:741-766 (in Japanese with English abstract).
43. Nakaya N, Soji N, Kaneko T. Efficacy and safety of NK-104 (pitavastatin), a novel HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. J Clin Ther Med 2001;17:767-787 (in Japanese with English abstract).
44. Nakaya N, Tateno M, Nakamura T, Kojima K. Pharmacokinetics of repeated Dose NK-104 (pitavastatin), in healthy elderly and non-elderly volunteers. J Clin Ther Med 2001;17:957-970 (in Japanese with English abstract).
45. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163: 157-164.
46. Ohnaka K, Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biochim Res Comm 2001;287:337-342.
47. Ooyen C, Zecca A, Bersino AM, Catapano AL: NK-104, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis 1999;145: 87-93.
48. Ouchi Y, Saito Y, Ito H, Yamada N. Efficacy and safety of NK-104 (pitavastatin), a new HMG-CoA reductase inhibitor in the elderly patients with hyperlipidemia. Geriatr Med 2001;39:849-860 (in Japanese with English abstract).
49. Pogson GW, Kindred LH, Carper BD. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999;83:1146.
50. Prueksaritanont T, Subramanian R, Fang X. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-512.
51. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-1051.
52. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
53. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Arzneimittelforschung 2002;52:251-255.
54. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162: 373-379.
55. Sakaeda T, Takara K, Kakumoto M, et al. Simvastatin and lovastatin, but not pravastatin, interact with MDRI. J Pharm Pharmacol 2002;54:419-423.
56. Sasaki J, Ikeda Y, Yamamoto K, Ageta M, Arakawa K. Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia; randomized double-blind, cross-over placebo-controlled study. Atherosclerosis 2000;151:73 (Abstract).
57. Scandinavian Simvastatin Survival Study Writing Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
58. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-1307.
59. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-1630.
60. Shimada Y, Koga T, Tabata F: Partition coefficient and hepatic cell-selectivity of HMG-CoA Reductase inhibitors. Progr Med 1996;18:957-962 (in Japanese with English abstract).
61. Siedlik PH, Olson SC, Yang BB. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999;39:501-504.
62. Sone H, Takahashi A, Shimano H. et al. HMG-CoA reductase inhibitor decreases small low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002;71:2403-2412.
63. Suzuki M, Yanagawa Y, Iwasaki H, et al. First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxypentenoic acid chain, associated with a potent synthetic statin NK-104. Bioorg Med Chem Lett 1999;9:2977-2982.
64. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146:259-270.
65. Suzuki M, Iwasaki H, Fujikawa Y, Kitahara M, Sakashita M, Sakoda: Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg Med Chem Lett 2001;9:2727-2743.
66. Suzuki H, Yamazaki H, Aoki T, et al. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in guinea pigs. Arzneimittelforschung 2001;51:38-45.
67. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K: Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003;10:108-115.
68. Takemoto M, Kitahara M, Yokote K, et al. S. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 2001;133: 83-88.
69. Teramoto T, Saito Y, Nakaya N. the Japan Itavastatin Clinical Study Group. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia. Atherosclerosis 2000;151:53 (Abstract).
70. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
71. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
72. Transon C, Leeman T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450 (CYP2C9) by fluvastatin. Clin Pharmacol Ther 1995;58:412-417.
73. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA inhibitors. Eur J Clin Pharmacol 1996;50:209-215.
74. Wang E, Lew K, Casciano CN, Clement RP, Johnson WW. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol 2001;14:1596-1603.
75. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800-806.
76. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002;30:1352-1356.
77. Wen X, Wang JS, Backman JT, Kivisto K, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359-1361.
78. Yamamoto K, Todaka N, Goto H, et al. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglycerides secretion and fatty acid oxidation in rat liver. Life Sci 1999;65:1493-1520.
79. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 2003;10: 37-42.
80. Yanagita T, Hara E, Yotsumoto H, et al. NK-104, a potent new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from Hep G2 cells. Curr Ther Res 1999;60:423-434.